JP2013533305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533305A5 JP2013533305A5 JP2013523660A JP2013523660A JP2013533305A5 JP 2013533305 A5 JP2013533305 A5 JP 2013533305A5 JP 2013523660 A JP2013523660 A JP 2013523660A JP 2013523660 A JP2013523660 A JP 2013523660A JP 2013533305 A5 JP2013533305 A5 JP 2013533305A5
- Authority
- JP
- Japan
- Prior art keywords
- adra2a
- antagonist
- liver
- individual
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 208000019423 liver disease Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 210000004185 liver Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 102100024401 Alpha-1D adrenergic receptor Human genes 0.000 claims 1
- 102100022815 Alpha-2A adrenergic receptor Human genes 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 101000689696 Homo sapiens Alpha-1D adrenergic receptor Proteins 0.000 claims 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000002767 hepatic artery Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical group C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims 1
- 229960000317 yohimbine Drugs 0.000 claims 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1013573.9 | 2010-08-12 | ||
| GBGB1013573.9A GB201013573D0 (en) | 2010-08-12 | 2010-08-12 | Treatment |
| PCT/GB2011/001217 WO2012020235A1 (en) | 2010-08-12 | 2011-08-12 | Treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533305A JP2013533305A (ja) | 2013-08-22 |
| JP2013533305A5 true JP2013533305A5 (enExample) | 2014-09-18 |
Family
ID=42937912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523660A Pending JP2013533305A (ja) | 2010-08-12 | 2011-08-12 | 治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130237557A1 (enExample) |
| EP (1) | EP2603210A1 (enExample) |
| JP (1) | JP2013533305A (enExample) |
| GB (1) | GB201013573D0 (enExample) |
| WO (1) | WO2012020235A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014120642A1 (en) * | 2013-01-30 | 2014-08-07 | The General Hospital Corporation | Diagnosis and treatment of hepatorenal syndrome |
| CA2978597A1 (en) * | 2015-03-06 | 2016-09-15 | Georgia State University Research Foundation, Inc. | Integrin-targeting protein and methods of use thereof |
| GB201804922D0 (en) | 2018-03-27 | 2018-05-09 | Ucl Business Plc | Traatment |
| WO2020216669A1 (de) * | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| EP4127134A4 (en) * | 2020-04-01 | 2024-07-31 | Alnylam Pharmaceuticals, Inc. | COMPOSITIONS OF ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) ARNI AGENTS AND METHODS OF USE THEREOF |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| WO1996038579A1 (en) | 1995-06-02 | 1996-12-05 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
| US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| CA2538415A1 (en) * | 2003-09-15 | 2005-03-24 | Wilfred Wayne Lautt | Use of antagonists of hepatic sympathetic nerve activity |
| US9107917B2 (en) * | 2005-05-13 | 2015-08-18 | The Feinstein Institute For Medical Research | Treatment of sepsis and inflammation with alpha2A adrenergic antagonists |
-
2010
- 2010-08-12 GB GBGB1013573.9A patent/GB201013573D0/en not_active Ceased
-
2011
- 2011-08-12 US US13/816,708 patent/US20130237557A1/en not_active Abandoned
- 2011-08-12 JP JP2013523660A patent/JP2013533305A/ja active Pending
- 2011-08-12 EP EP11748700.9A patent/EP2603210A1/en not_active Withdrawn
- 2011-08-12 WO PCT/GB2011/001217 patent/WO2012020235A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma | |
| Chen et al. | The harmful effects of subarachnoid hemorrhage on extracerebral organs | |
| Naya et al. | Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients | |
| JP2013533305A5 (enExample) | ||
| Ee et al. | Leukotriene B4 mediates macrophage influx and pulmonary hypertension in bleomycin-induced chronic neonatal lung injury | |
| Ow et al. | Determinants of renal tissue hypoxia in a rat model of polycystic kidney disease | |
| Redfors et al. | Cardioprotective effects of isoflurane in a rat model of stress-induced cardiomyopathy (takotsubo) | |
| Babiker et al. | Effects of cardiac hypertrophy, diabetes, aging, and pregnancy on the cardioprotective effects of postconditioning in male and female rats | |
| Tay et al. | The chick chorioallantoic membrane imaging method as a platform to evaluate vasoactivity and assess irritancy of compounds | |
| Eshraghi et al. | Circular RNAs: a small piece in the heart failure puzzle | |
| Lu et al. | Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function | |
| Thompson et al. | A 40-year-old man with albinism and progressive dyspnea | |
| Lavine et al. | The effect of acute hypertension on left ventricular diastolic pressures in a canine model of left ventricular dysfunction with a preserved ejection fraction and elevated left ventricular filling pressures | |
| JP2012127879A (ja) | 腎症の進行度の判定方法並びに線維化抑制剤。 | |
| Subbotina | Renal Sympathetic Denervation. Quality of Life, Hypertensive Heart Disease and Biomarker Discovery | |
| Manolakopoulos et al. | 1354 HEPATITIS C VIRUS REINFECTION FOLLOWING SUSTAINED VIROLOGICAL RESPONSE IN INTRAVENOUS DRUG USERS | |
| ENUGANTI | DIAGNOSIS AND THERAPEUTIC MANAGEMENT OF HEART FAILURE INDOGS | |
| Clayton et al. | Establishing Safety and Efficacy of a Human Platelet-Derived Growth Factor-AB-Conjugated Plasma Polymerised Nanocarrier for Cardiac Regeneration | |
| Dauz | The Role of Transforming-growth Factor Beta 1 and Platelet-derived Growth Factor in Right Ventricular Remodeling in Response to Right Ventricular Pressure and Volume-loading | |
| Burger et al. | A11518 Hemodialysis reduces levels of circulating microparticles in individuals with hypertension | |
| Cabassi et al. | PP. 11.18: ALTERED WATER BALANCE IN PREHYPERTENSIVE SPONTANEOUSLY HYPERTENSIVE RATS | |
| Karakurt | [LB. 03.04] MODULATION OF MEMBRANE PROTEIN EXPRESSIONS IN ALDOSTERONE INDUCED HUMAN KIDNEY CELL VIA MICRORNAS | |
| Cuspidi et al. | Aortic Root Dilatation in Hypertensive Patients: A Multicenter Survey in Echocardiographic Practice: 9B. 01 | |
| Tsioufis et al. | RENAL FLOW RESERVE IS ASSOCIATED WITH ADMA LEVELS IN HYPERTENSION. AN INVASIVE APPROACH OF RENAL MICROCIRCULATION: 9B. 02 | |
| Song et al. | Imaging Diagnosis of Unusual Form of Right-divisional Intrahepatic Portosystemic Shunt in a Bichon Frise |